TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SODIUM OXYBATE

SODIUM OXYBATE
Approved 2017-01-17
3
Indications
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2017-01-17
Routes
ORAL
Dosage Forms
SOLUTION

SODIUM OXYBATE Approval History

Loading approval history...

What SODIUM OXYBATE Treats

2 indications

SODIUM OXYBATE is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cataplexy
  • Narcolepsy
Source: FDA Label

SODIUM OXYBATE Boxed Warning

CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION and ABUSE AND MISUSE. Central Nervous System Depression Sodium oxybate oral solution is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with sodium oxybate oral solution [see Warnings and Precautions (5.1) ] . Many patients who received sodium oxybate oral solution during clinical trials in narcolepsy were receiving central nervous system stimulants ...

Drugs Similar to SODIUM OXYBATE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

LUMRYZ
SODIUM OXYBATE
2 shared
AVADEL CNS
Shared indications:
CataplexyNarcolepsy
WAKIX
PITOLISANT HYDROCHLORIDE
2 shared
HARMONY
Shared indications:
CataplexyNarcolepsy
XYREM
SODIUM OXYBATE
2 shared
JAZZ PHARMS
Shared indications:
CataplexyNarcolepsy
XYWAV
CALCIUM OXYBATE
2 shared
JAZZ
Shared indications:
CataplexyNarcolepsy
ADDERALL XR 10
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
ADDERALL XR 15
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
ADDERALL XR 20
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
ADDERALL XR 25
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
ADDERALL XR 30
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
ADDERALL XR 5
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Narcolepsy
AMPHETAMINE SULFATE
AMPHETAMINE SULFATE
1 shared
PRINSTON INC
Shared indications:
Narcolepsy
DEXEDRINE SPANSULE
DEXTROAMPHETAMINE SULFATE
1 shared
IMPAX LABS INC
Shared indications:
Narcolepsy
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE SULFATE
1 shared
SPECGX LLC
Shared indications:
Narcolepsy
DYANAVEL XR 10
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Narcolepsy
DYANAVEL XR 15
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Narcolepsy
DYANAVEL XR 20
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Narcolepsy
DYANAVEL XR 5
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Narcolepsy
EVEKEO
AMPHETAMINE SULFATE
1 shared
AZURITY
Shared indications:
Narcolepsy
METHYLIN
METHYLPHENIDATE HYDROCHLORIDE
1 shared
SPECGX LLC
Shared indications:
Narcolepsy
NUVIGIL
ARMODAFINIL
1 shared
NUVO PHARMS
Shared indications:
Narcolepsy
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SODIUM OXYBATE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Jazz Pharmaceuticals Inc.’s XYREM (sodium oxybate) Oral Solution. However, due to Jazz Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy .

⚠️ BOXED WARNING

WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION and ABUSE AND MISUSE. Central Nervous System Depression Sodium oxybate oral solution is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with so...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.